scholarly journals An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor– or Serotonin-Norepinephrine Reuptake Inhibitor–Resistant Depression in Adult Women

2017 ◽  
Vol 37 (5) ◽  
pp. 578-583 ◽  
Author(s):  
Brent M. Kious ◽  
Hana Sabic ◽  
Young-Hoon Sung ◽  
Douglas G. Kondo ◽  
Perry Renshaw
Keyword(s):  
Pilot Study ◽  
Selective Serotonin Reuptake Inhibitor ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Adult Women ◽  
Open Label ◽  
Norepinephrine Reuptake Inhibitor ◽  
Resistant Depression ◽  
Serotonin Norepinephrine Reuptake Inhibitor ◽  
Norepinephrine Reuptake

Psychopharmacology of Depression in the Next Millennium

CNS Spectrums ◽  
1999 ◽  
Vol 4 (7) ◽  
pp. 21-35
Author(s):  
Paul J. Goodnick
Keyword(s):  
Substance P ◽  
20Th Century ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Corticotropin Releasing Factor ◽  
Treatment Of Depression ◽  
Norepinephrine Reuptake Inhibitor ◽  
Developing Directions ◽  
Serotonin Norepinephrine Reuptake Inhibitor ◽  
Norepinephrine Reuptake

AbstractOver the last half of the 20th century, there have been a series of psychopharmacologic strategies for treatment of depression. As we approach the next century, new therapies in varying stages of American release are being developed. This review will focus on information available for the following proposed antidepressants: 1) reboxetine, a norepinephrine selective reuptake inhibitor; 2) milnacipran, a combined serotonin/norepinephrine reuptake inhibitor; 3) a new enantiomer of fluoxetine, a selective serotonin reuptake inhibitor; 4) duloxetine, another combined serotonin/norepinephrine reuptake inhibitor; 5) sunepitron, a combined 5-HT1A agonist and α2 antagonist; and, 6) MK-869, a substance P inhibitor. Finally, other possible developing directions will be reviewed, including corticotropin-releasing factor.

Sign in / Sign up

Export Citation Format

Share Document